AstraZeneca plc

Introduction
AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Formed in 1999 through the merger of Sweden’s Astra AB and the UK’s Zeneca Group, AstraZeneca is recognized for its expertise in oncology, cardiovascular, respiratory, renal, and immunology therapies. The company gained worldwide recognition for its role in developing a widely distributed COVID-19 vaccine in collaboration with the University of Oxford.

Mission and Vision

Mission: To push the boundaries of science to deliver life-changing medicines.
Vision: To transform the future of healthcare by being a global leader in biopharmaceutical innovation.

Products and Services

Oncology: Leading cancer therapies including Tagrisso, Imfinzi, and Lynparza.
Cardiovascular, Renal & Metabolism (CVRM): Medicines for heart failure, diabetes, and kidney disease.
Respiratory & Immunology: Treatments for asthma, COPD, and autoimmune conditions.
COVID-19 Vaccine: Vaxzevria (Oxford-AstraZeneca vaccine), distributed globally.
Rare Diseases: Through the acquisition of Alexion Pharmaceuticals (2021), expanding into immunology and rare genetic disorders.

Growth and Innovation
AstraZeneca invests heavily in biologics, immunotherapy, and precision medicine, with oncology as its largest business segment. The acquisition of Alexion strengthened its position in rare disease research. AstraZeneca has also embraced AI and digital health technologies to accelerate drug discovery and patient care solutions.

Global Impact
With operations in over 100 countries and medicines used by millions worldwide, AstraZeneca has a profound global reach. The company played a critical role in global health during the COVID-19 pandemic, distributing billions of vaccine doses, especially to low- and middle-income countries. AstraZeneca is also committed to sustainability, aiming for zero carbon emissions from global operations by 2025.